Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity after Radiotherapy for Clinically Localized Prostate Cancer

Urology

Volumn 87, Issue , 2016, Pages 146-152

  Kohutek, Zachary A ^a   Weg, Emily S ^a   Pei, Xin ^a   Shi, Weiji ^a   Zhang, Zhigang ^a   Kollmeier, Marisa A ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; IODINE 125; IRIDIUM 192; LEUPRORELIN; PALLADIUM 103; ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORBIDITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NOMOGRAM; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; CANCER STAGING; CARDIOVASCULAR DISEASES; COMPLICATION; FORECASTING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR; TRENDS;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84959259562     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.08.029     Document Type: Article

References (31)

1. J.W. Denham, A. Steigler, D.S. Lamb, and et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
2. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827
3. M. Roach 3rd, K. Bae, J. Speight, and et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
4. G.N. Levine, A.V. D'Amico, P. Berger, and et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
5. H.K. Tsai, A.V. D'Amico, N. Sadetsky, Chen M.H., and P.R. Carroll Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516 1524
6. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
7. P.L. Nguyen, Y. Je, F.A. Schutz, and et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366
8. A.V. D'Amico, Chen M.H., A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
9. A. Nanda, Chen M.H., M.H. Braccioforte, B.J. Moran, and A.V. D'Amico Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
10. M.J. Zelefsky, H. Chan, M. Hunt, Y. Yamada, A.M. Shippy, and H. Amols Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419
11. Y. Yamada, S. Bhatia, M. Zaider, and et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer Brachytherapy 5 2006 157 164
12. M.J. Zelefsky, Y. Yamada, G. Cohen, and et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique Int J Radiat Oncol Biol Phys 48 2000 601 608
13. I. Deutsch, M.J. Zelefsky, Zhang Z., and et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT Brachytherapy 9 2010 313 318
14. M.J. Zelefsky, M.A. Nedelka, Z.L. Arican, and et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy Brachytherapy 7 2008 1 6
15. Liu L., S. Forman, and B. Barton Fitting Cox model using PROC PHREG and beyond in SAS SAS Global Forum 2009 Paper 236
16. D.R. Ziehr, Chen M.H., Zhang D., and et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer BJU Int 116 2015 358 365
17. J.A. Efstathiou, K. Bae, W.U. Shipley, and et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 54 2008 816 823
18. J.A. Efstathiou, K. Bae, W.U. Shipley, and et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
19. C.S. Saigal, J.L. Gore, T.L. Krupski, and et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500
20. C.G. Jespersen, M. Norgaard, and M. Borre Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study Eur Urol 65 2014 704 709
21. M. Van Hemelrijck, H. Garmo, L. Holmberg, and et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden J Clin Oncol 28 2010 3448 3456
22. E. Martin-Merino, S. Johansson, T. Morris, and L.A. Garcia Rodriguez Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care Drug Saf 34 2011 1061 1077
23. Zhao J., Zhu S., Sun L., and et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies PLoS ONE 9 2014 e107516
24. C. Bosco, Z. Bosnyak, A. Malmberg, J. Adolfsson, N.L. Keating, and M. Van Hemelrijck Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis Eur Urol 68 2015 386 396
25. D.C. Goff Jr, D.M. Lloyd-Jones, G. Bennett, and et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2935 2959
26. R.B. D'Agostino Sr, R.S. Vasan, M.J. Pencina, and et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 2008 743 753
27. M.V. Pilepich, K. Winter, C.A. Lawton, and et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
28. G.E. Hanks, T.F. Pajak, A. Porter, and et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
29. Z.S. Zumsteg, D.E. Spratt, Pei X., and et al. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy Int J Radiat Oncol Biol Phys 85 2013 1012 1017
30. D.E. Spratt, Z.S. Zumsteg, P. Ghadjar, and et al. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer BJU Int 114 2014 360 367
31. Z.S. Zumsteg, and M.J. Zelefsky Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 13 2012 e259 e269